p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: A potential marker of p53 tumor-suppressor gene function

Blood

Volumn 88, Issue 10, 1996, Pages 4012-4020

  Chilosi, Marco ^a   Doglioni, Claudio ^b   Magalini, Alba ^b   Inghirami, Giorgio ^b   Krampera, Mauro ^b   Nadali, Gianpaolo ^b   Rahal, Daoud ^b   Pedron, Serena ^b   Benedetti, Alice ^b   Scardoni, Maria ^b   Macrì, Ettore ^b   Lestani, Maurizio ^b   Menestrina, Fabio ^b   Pizzolo, Giovanni ^b   Scarpa, Aldo ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CYCLIN DEPENDENT KINASE; GENE PRODUCT; INHIBITOR PROTEIN; MONOCLONAL ANTIBODY; PROTEIN P21; PROTEIN P53;

ARTICLE; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 10544225750     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.10.4012.bloodjournal88104012     Document Type: Article

References (70)

1. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993
2. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potent mediator of p53 tumor suppression. Cell 75:817, 1993
3. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169, 1994
4. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366:701, 1993
5. Li R, Waga S, Hannon GJ, Beach D, Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534, 1994
6. Luo Y, Hurwitz J, Massagué J: Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 CIP1. Nature 375:159, 1995
7. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574, 1994
8. Chen J, Jackson PK, Kirschner MW, Dutta A: Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386, 1995
9. WAF-1 gene activities. Mol Cell Biol 16:1786, 1996
10. Dulic V, Kaufman WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013, 1994
11. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391, 1994
12. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018, 1995
13. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ: p53-independent expression of p21 Cip1 in muscle and other terminally differentiating cells. Science 267:1024, 1995
14. Li Y, Jenkins CW, Nichols MA, Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261, 1994
15. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318, 1993
16. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 84:2391, 1994
17. Imamura J, Miyoshi I, Koeffler P: p53 in hematologic malignancies. Blood 84:2412, 1994
18. Gaidano G, Ballerini P, Gong J, Inghirami G, Neri A, Newcomb E, Magrath I, Knowles D, Dalla Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
19. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux PH, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the p53 gene in B cell chronic lymphocytic leukemia. A report on 39 cases with cytogenetic analysis. Leukemia 6:246, 1992
20. Feanaux P, Jonveaux PH, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Berger R. Kerckaert JP: p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 78:1652, 1991
21. Jonveaux P, Feanaux P, Pignon JM, Lai JL, Quiquandon I, Kerckaert JP, Loucheux-Lefebvre MH, Goossens M, Bauters F, Berger R: Mutations of the p53 gene in myelodisplastic syndromes. Oncogene 6:2243, 1991
22. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H: Mutations of the p53 gene in myelodisplastic syndrome (MDS) and MDS-derived leukemia. Blood 81:3022, 1993
23. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580, 1995
24. Neubauer A, He M, Schmidt CA, Huhn D, Liu ET: Genetic alterations in the p53 gene in the blast chrisis of chronic myelogenous leukemia: Analysis by polymerase reaction based techniques. Leukemia 7:593, 1993
25. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen D-L, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig W-D, Reiter A, Mizoguchi H, Koeffler HP: Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82:3163, 1993
26. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
27. El-Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
28. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeid M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994, 1993
29. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao L-E, Yu AL: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 84:3105, 1994
30. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VVVS, Schluger A, Chaganti RSK: p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 86:2892, 1995
31. Du M, Peng H, Singh N, Isaacson PG, Pan L: The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 86:4587, 1995
32. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T: p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703, 1994
33. Lowe SW, Ruley HE, Jacks T, Houseman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957, 1993
34. Fung CY, Fisher DE: p53: From molecular mechanisms to prognosis in cancer. J Clin Oncol 13:808, 1995
35. Lowe SW, Bodis S, McClatchey A, Remington L, Earl Ruley H, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807, 1994
36. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Traveli S, Deisseroth AB, Mercer WE: p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55:668, 1995
37. Sheikh MS, Rochefort H, Garcia M: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11:1899, 1995
38. Fan S, el Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824, 1994
39. Doglioni C, Pelosio P, Mombello A, Scarpa A, Chilosi M: Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematol Pathol 5:67, 1991
40. Said JW, Barrera R, Shintaku IP, Nakamura H, Koeffler HP: Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 141:1343, 1992
41. Gong JZ, Zhou H, Hu Z, Schulman P, Vinceguerra V, Broome JD, Koduru P: Absence of somatic changes in p21 gene in non-Hodgkin's lymphoma and chronic myelogenous leukemia. Hematol Pathol 9:171, 1995
42. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen D-L, Vogelstein B, Koeffler HP: Absence of WAF1 mutations in a variety of human malignancies. Blood 84:3781, 1994
43. Harris NL, Jaffe ES, Stein H, Banks P, Chan KC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
44. Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, Barbareschi M, Scarpa A, Mariuzzi GM, Pizzolo G: Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood 84:4295, 1994
45. Chilosi M, Mombello A, Montagna L, Benedetti A, Lestani M, Semenzato G, Menestrina F: Multimarker immunohistochemical staining of calgranulins, chloroacetate esterase, and S100 for simultaneous demonstration of inflammatory cells on paraffin sections. J Histochem Cytochem 38:1669, 1990
46. Scarpa A, Capelli P, Zamboni G, Oda T, Mukai K, Bonetti F, Martignoni G, Iacono C, Serio G, Hirohashi S: Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. Am J Pathol 142:1163, 1993
47. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 142:1534, 1993
48. Hayashi K, Orita M, Suzuki Y, Sekiya T: Use of labeled primers in polymerase reaction (LP-PCR) for a rapid detection of the products. Nucleic Acids Res 17:3605, 1989
49. Suzuki Y, Sekiya T, Hayashi K: Allele-specific polymerase chain reaction: A method for amplification and sequence determination of a single component among a mixture of sequence variants. Anal Biochem 192:82, 1991
50. Cesarman E, Inghirami G, Chadburn A, Knowles DM: High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:845, 1993
51. Matsushima AY, Cesarman E, Chadburn A, Knowles DM: Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 144:573, 1994
52. Lohmann D, Ruhri C, Schmitt M, Graeff H, Hofler H: Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Occurrence of false-positives and false-negatives. Diagn Mol Pathol 2:36, 1993
53. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? Revisited. J Pathol 172:1, 1994
54. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, Orradre JL, Garcia P, Lopez C, Martinez P: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 82:3151, 1993
55. Preudhomme C, Dervite I, Wattel E, Varumbeke M, Flactif M, Lai JL, Hecquet B, Coppin MC, Nelken B, Gosselin B, Fenaux P: Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: A report of 48 cases. J Clin Oncol 13:812, 1995
56. Fields S, Jang SK: Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046, 1990
57. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C: A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7:2565, 1993
58. Pavletich NP, Chambers KA, Pabo CO: The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7:2556, 1993
59. Wang Y, Reed M, Wang P, Stenger JE, Mayr G, Anderson ME, Schwedes FJ, Tegtmeyer P: p53 domains: Identification and characterization of two autonomous DNA-binding regions. Genes Dev 7:2575, 1993
60. Unger T, Nau MM, Segal S, Minna JD: p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11:1383, 1992
61. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP: Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9:1899, 1994
62. Srinivasan R, Maxwell SA: A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region. Oncogene 12:193, 1996
63. DiGiuseppe JA, Redstone MS, Yeo CJ, Kern SE, Hruban RH: p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 147:884, 1995
64. Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, Harris CC: Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10:2103, 1995
65. Soddu S, Blandino G, Scardigli G, Martinelli R, Rizzo MG, Crescenzi M, Sacchi A: Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes. Mol Cell Biol 16:487, 1996
66. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491, 1992
67. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847, 1993
68. Guillouf C, Grana X, Selvakumaran M, De Luca A, Giordano A, Hoffman B, Liebermann DA: Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: Blocking p53-induced apoptosis unmasks G1 arrest. Blood 85:2691, 1995
69. Blagosklonny M, Toretsky J, Neckers L: Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11:933, 1995
70. Goldberg Y, Nassif II, Pittas A, Tsai L-L, Dynlacht BD, Rigas B, Shiff SJ: The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12:893, 1996